01What the condition is
Male pattern hair loss, androgenetic alopecia, is a common condition in which genetically susceptible follicles progressively miniaturise under androgen influence, producing the recognised pattern of temple recession and vertex thinning. It is progressive, it is not caused by hats, poor circulation or shampoo, and it is not a disease of hygiene.
Understanding that it is progressive matters commercially as well as clinically. Any intervention is being applied against a background of ongoing change, which is why treatments that work require continuous use and why a transplant performed without planning for future loss can look worse in a decade than it did at six months.
02The treatments with evidence
A small number of licensed medicines have an established evidence base in androgenetic alopecia. In the UK these are regulated by the MHRA, and the oral option requires a prescription and a discussion about side effects, including sexual side effects, which are documented and which some men experience.
Both act against the process rather than reversing it, both require continuous use, and both produce their best results earlier in the course of loss rather than later. Anyone taking this seriously should be having the conversation with a prescriber, not with a marketplace.
03What is sold alongside them
The market around hair loss is very large and mostly consists of cosmetics. Thickening shampoos, scalp serums, caffeine formulations, supplement stacks, fibres, laser combs, derma rollers and a broad category of clinic delivered injectable treatments marketed for hair.
These are not equivalent to each other and should not be assessed as a category. Some have limited human evidence, some have laboratory rationale only, and some have effectively none. What they share is that they are not licensed medicines for the condition, which is why their claims concern appearance, volume, thickness and scalp condition rather than treating hair loss.
04Reading the claim wording
The wording on hair products is unusually informative because the regulatory boundary is unusually sharp. A product claiming to treat or prevent hair loss is making a medicinal claim and would require authorisation. A product claiming to improve the appearance of thickness, to support scalp health or to reduce breakage is making a cosmetic claim.
Reading which type of claim is being made tells you what the manufacturer believes it can substantiate. This is the same mechanism described in phrases with no fixed meaning, and hair loss is where it is easiest to see in action.
05Surgery, and the finite resource problem
Hair transplantation moves follicles from an area less affected by androgen sensitivity into an area that is. It does not create new follicles, which means the donor area is a finite resource and every procedure spends some of it.
The consequences follow logically. A transplant performed early, without medical treatment to slow ongoing loss, can produce a result that separates from the receding native hair around it over subsequent years. Planning for the pattern at sixty rather than the pattern at thirty is what distinguishes careful practice, and it is a question a patient can ask directly. Overseas surgery raises additional questions about follow up and about who manages a complication after the flight home.
06Hair loss that is not male pattern
Not all hair loss is androgenetic. Alopecia areata produces well demarcated patches and is an autoimmune condition. Telogen effluvium produces diffuse shedding some months after a physiological stressor such as illness, surgery, significant weight loss or severe stress. Scarring alopecias destroy follicles and are urgent because the damage is permanent. Thyroid disease and iron deficiency can contribute.
Sudden loss, patchy loss, loss with scaling, redness, pain or scarring, and loss in an unusual distribution all warrant a GP appointment rather than a product. This is the single most important paragraph in the article, because treating a non androgenetic cause with an androgenetic treatment wastes the window in which something useful could have been done.
07Scalp condition, which is a separate variable
Seborrhoeic dermatitis, psoriasis and simple irritation from products are common, treatable, and frequently conflated with hair loss because both are noticed at the same time in the same mirror. Treating the scalp condition does not treat androgenetic loss, but it removes inflammation and scratching and makes the hair look better, which is worth doing on its own terms.
The scalp article covers this in detail, including why antifungal treatment needs contact time with skin rather than hair: the shampoo question.
08Why this market behaves as it does
Hair loss combines a visible, progressive, emotionally significant change with a treatment window that closes as loss advances. That combination produces urgency, and urgency is commercially valuable. It is the reason this category carries so much subscription selling, so many bundles and so much before and after imagery.
The reasonable response is to separate the medical question from the purchasing question. The medical question has a small number of evidenced answers and belongs with a prescriber. Everything else is optional, and optional purchases made under urgency are the ones people regret.
09Setting expectations properly
- Evidenced treatments slow and partially reverse. They do not restore a hairline from a decade ago.
- They require continuous use, and benefit is lost on stopping.
- Earlier intervention outperforms later intervention.
- Surgery moves a finite resource and should be planned against future loss.
- Anything sudden, patchy, painful or scarring is a GP question, not a product question.
Accepting a receding hairline is also a legitimate option, and it is the only one with no side effects, no ongoing cost and no maintenance. It is worth naming, because the market never does.